<SEC-DOCUMENT>0001019687-12-002502.txt : 20120727
<SEC-HEADER>0001019687-12-002502.hdr.sgml : 20120727
<ACCEPTANCE-DATETIME>20120727135659
ACCESSION NUMBER:		0001019687-12-002502
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20120724
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120727
DATE AS OF CHANGE:		20120727

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AETHLON MEDICAL INC
		CENTRAL INDEX KEY:			0000882291
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				133632859
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21846
		FILM NUMBER:		12989946

	BUSINESS ADDRESS:	
		STREET 1:		8910 UNIVERSITY CENTER LANE, SUITE 660
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92122
		BUSINESS PHONE:		858-459-7800

	MAIL ADDRESS:	
		STREET 1:		8910 UNIVERSITY CENTER LANE, SUITE 660
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92122

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BISHOP EQUITIES INC
		DATE OF NAME CHANGE:	19930602
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>aethlon_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section&nbsp;13 or 15(d)&nbsp;of
the Securities Exchange Act of 1934</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
July 24, 2012</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AETHLON MEDICAL, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 32%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 32%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 32%; font-size: 10pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Nevada</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">of incorporation)</P></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">000-21846</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Commission File Number)</P></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">13-3632859</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(IRS Employer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification Number)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 45%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 10%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 45%; font-size: 10pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">8910 University Center Lane, Suite 660</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">San Diego, California</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">92122</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Zip Code)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Registrant&rsquo;s telephone number, including
area code: (858) 459-7800</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Not applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Former name or former address, if changed
since last report.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2 below):</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 97%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">FORWARD-LOOKING STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Form 8-K and other reports filed by
the Registrant from time to time with the Securities and Exchange Commission (collectively the &quot;Filings&quot;) contain or
may contain forward-looking statements and information that are based upon beliefs of, and information currently available to,
the Registrant's management as well as estimates and assumptions made by the Registrant's management. When used in the Filings,
the words &ldquo;anticipate,&rdquo; &quot;believe,&quot; &quot;estimate,&quot; &quot;expect,&quot; &quot;future,&quot; &quot;intend,&quot;
&quot;plan&quot; or the negative of these terms and similar expressions as they relate to the Registrant or the Registrant's management
identify forward-looking statements. Such statements reflect the current view of the Registrant with respect to future events and
are subject to risks, uncertainties, assumptions and other factors relating to the Registrant's industry, the Registrant's operations
and results of operations and any businesses that may be acquired by the Registrant. Should one or more of these risks or uncertainties
materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated,
believed, estimated, expected, intended or planned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Although the Registrant believes that the
expectations reflected in the forward-looking statements are reasonable, the Registrant cannot guarantee future results, levels
of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States,
the Registrant does not intend to update any of the forward-looking statements to conform these statements to actual results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%"><FONT STYLE="font-weight: normal">ITEM 5.02</FONT></TD>
    <TD STYLE="width: 90%"><FONT STYLE="font-weight: normal">DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Effective July 24, 2012, Mr. Philip Ward
and Mr. Thomas Wornham were elected to the Board of Directors (the &ldquo;Board&rdquo;) of Aethlon Medical, Inc. (the &ldquo;Registrant&rdquo;).
Messrs. Ward and Wornham were elected by the unanimous vote of the Board, filling the two vacancies created by the Board&rsquo;s
determination to expand the Board of Directors and fix the number of Directors on the Board at seven as permitted by the amendment
of the Registrant&rsquo;s By-laws discussed in Item 5.03 below. The election of Messrs. Ward and Wornham to the Board brings the
total number of Directors to seven. Each will serve until his resignation or removal, or until his successor is duly elected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Mr. Wornham recently retired as Executive
Vice President &amp; Regional Manager at Wells Fargo Bank in San Diego, representing the culmination of an exemplary career that
spanned three decades. At Wells Fargo, Mr. Wornham&rsquo;s team provided financial solutions to diverse industry organizations
whose annual revenues ranged between $10 million and $1 billion dollars. Included among these organizations are public and private
life science, biotechnology and medical device companies located throughout San Diego, Imperial, and Southern Riverside Counties.
Mr. Wornham is also an active civic leader. He is currently Vice Chair of the San Diego Water Authority and the past Chairman of
the San Diego Regional Chamber of Commerce, The Century Club of San Diego, and the San Diego Regional Economic Development Corporation.
Mr. Wornham graduated from University of California Berkeley, with a BA Political Science in 1982.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Mr. Ward is the former Chairman and CEO
of Bignell-Ward-Bignell Corporation; former President and CEO of Hawk Financial Services Corporation, a premium finance company;
former Executive Director and COO of Investments of Golden Eagle Insurance Corporation, a property and casualty California insurance
company; and former Executive Vice President and COO Finance of Big Bear Supermarkets, where he was also in charge of acquisitions,
as well as leasing and sales of all operating units and real properties.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On June 26, 2012, the Registrant and Mr.
Wornham entered into a unit subscription agreement pursuant to which Mr. Wornham purchased $10,000 of units (the &ldquo;Units&rdquo;),
with each Unit consisting of (1) one share of Common Stock at a price per share of $0.072 and (2) a warrant to purchase that number
of shares of Common Stock (the &ldquo;Warrant Shares&rdquo;) as shall equal (a) 50% of the subscription amount divided by (b) $0.072
at an exercise price of $0.107 per Warrant Share. Mr. Wornham does not own any other securities of the Registrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On May 21, 2010, the Registrant issued 1,599,348
shares of Common Stock to Mr. Ward upon his exercise of certain warrants held by him at an aggregate exercise price of $283,600.
In connection with the exercise of those warrants, the Registrant (1) issued to Mr. Ward warrants to acquire 100,000 shares of
Common Stock at an exercise price of $0.176 per share, 194,118 shares of Common Stock at an exercise price of $0.17 per share and
555,556 shares of Common Stock at an exercise price of $0.18 per share, all of which warrants expire May 7, 2015, and (2) extended
to July 1, 2018 the expiration date of other warrants held by Mr. Ward to acquire 194,118 shares of Common Stock at an exercise
price of $0.17 per share and 555,556 shares of Common Stock at an exercise price of $0.18 per share. On February 14, 2011, the
Registrant issued 245,555 shares of Common Stock to Mr. Ward upon his exercise of certain warrants held by him at an aggregate
exercise price of $36,833. On July 6, 2011, the Registrant issued to Mr. Ward a convertible promissory note in the principal amount
of $100,000, convertible into Common Stock at a conversion price of $0.09 per share, and warrants to acquire 1,111,111 shares of
Common Stock at an exercise price of $0.125 per share, which warrants expire July 5, 2016, for a total purchase price of $100,000.
On August 15, 2011, the Registrant issued to Mr. Ward a convertible promissory note in the principal amount of $157,656.14, convertible
into Common Stock at a conversion price of $0.09 per share, and warrants to acquire 1,751,735 shares of Common Stock at an exercise
price of $0.125 per share, which warrants expire August 14, 2016, for a total purchase price of $157,656.14. On May 21, 2012, the
Registrant issued 1,000,000 shares of Common Stock to Mr. Ward at a price of $0.09 per share as payment for 18 months&rsquo; of
services rendered to the Registrant by Mr. Ward under a Consulting and Non-Disclosure Agreement (the &ldquo;Consulting Agreement&rdquo;)
entered into by Mr. Ward and the Registrant on July 6, 2011. The Consulting Agreement provided for payment to Mr. Ward of $5,000
worth of Common Stock per month, valued based on the average closing price of the Common Stock on the last three trading days of
each month, and was terminated in May 2012. Additional information regarding Mr. Ward&rsquo;s security ownership in the Registrant
can be viewed in the Registrant&rsquo;s Annual Report on Form 10-K filed on June 29, 2012 and in Mr. Ward&rsquo;s filings pursuant
to Section 16 of the Securities Exchange Act of 1934, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In connection with their election to the
Board, Messrs. Ward and Wornham will be entitled to receive compensation, including equity compensation, under the Registrant&rsquo;s
Board compensation program. On July 24, 2012, the Board approved a new Directors Compensation Program (the &ldquo;New Program&rdquo;),
which modifies and supersedes the 2005 Directors Compensation Program (the &ldquo;2005 Program&rdquo;) that was previously in effect.
Under the New Program, in which only non-employee Directors may participate, an eligible Director will receive a grant of $15,000
worth of options to acquire shares of Common Stock, with such grant being valued at the exercise price based on the average of
the closing bid prices of the Common Stock for the five trading days preceding the first day of the fiscal year; however for Mr.
Ward and Mr. Wornham, the exercise price for this initial grant, $0.076 per share, is based on the average of the closing bid prices
of the Common Stock for the five trading days preceding the date of their appointment (July 24, 2012). These options will have
a term of ten years and will be fully vested upon grant. In addition, each existing eligible Director (Mr. Franklyn Barry and Mr.
Edward Broenniman) will receive the same grant of $15,000 worth of options to acquire shares of Common Stock, with such grant being
valued at the exercise price based on the average of the closing bid prices of the Common Stock for the five trading days preceding
the first day of the fiscal year; provided however that for this current grant only, all of such grants shall be made at an exercise
price of $0.076 per share based on the average of the closing bid prices of the Common Stock for the five trading days preceding
the date of Mr. Ward's and Mr. Wornham's appointment (July 24, 2012).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">At the beginning of each fiscal year, each
Director eligible to participate in the New Program also will receive a grant of $20,000 worth of options valued at the exercise
price based on the average of the closing bid prices of the Common Stock for the five trading days preceding the first day of the
fiscal year. However, with respect to the new Directors and with respect to Mr. Barry and Mr. Broenniman, and for the current fiscal
year only, all of these grants shall be made at an exercise price of $0.076 per share based on the average of the closing bid prices
of the Common Stock for the five trading days preceding the date of Mr. Ward's and Mr. Wornham's appointment (July 24, 2012). Such
options will vest at the end of the applicable fiscal year provided that the Director has attended at least 80% of the Board meetings
held that year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, under the New Program eligible
Directors will receive cash compensation equal to $500 for each committee meeting attended and $1,000 for each formal Board meeting
attended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The New Program eliminates the following
features of the 2005 Program: (1) the annual payment of $10,000 in cash compensation and (2) the granting of options to Directors
based on a percentage of the issued and outstanding common stock of the Registrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On July 27, 2012, the
Registrant issued a press release announcing the election of Messrs. Ward and Wornham to the Registrant&rsquo;s Board. The
full text of the press release is set forth in Exhibit 99 attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%"><FONT STYLE="font-weight: normal">ITEM 5.03</FONT></TD>
    <TD STYLE="width: 90%"><FONT STYLE="font-weight: normal">AMENDMENTS TO ARTICLES OF INCORPORATION OR BYLAWS; CHANGE IN FISCAL YEAR.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Effective July 24, 2012, the Board unanimously
approved an amendment to Section 1 of Article III of the Registrant&rsquo;s By-Laws (the &ldquo;By-Laws&rdquo;). Prior to the amendment,
the By-Laws provided that the Board was to consist of at least one Director. The By-Laws amendment provides that the Board shall
consist of no less than one Director and that the number of Directors shall be fixed by resolution of the Board from time to time.
On July 24, 2012, the Board fixed the number of Directors of the Board at seven, thereby creating two vacancies on the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This summary is qualified in its entirety
by reference to the full text of (i) the By-Laws as filed with the Securities and Exchange Commission on November 16, 2009 as Exhibit
3.2 to the Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2009, and (ii) the First Amendment
to the By-Laws, a copy of which is attached to this Current Report on Form 8-K as Exhibit 3. The full text of each of these documents
is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 10%"><FONT STYLE="font-weight: normal">ITEM 9.01</FONT></TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 90%"><FONT STYLE="font-weight: normal">FINANCIAL STATEMENTS AND EXHIBITS.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-weight: normal">(d) EXHIBITS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp; &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-weight: normal">EXHIBIT NO.</FONT> <FONT STYLE="font-weight: normal">DESCRIPTION</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 10%"><FONT STYLE="font-weight: normal">3</FONT></TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 90%"><FONT STYLE="font-weight: normal">First Amendment to By-Laws of Aethlon Medical, Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">99</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">Press Release dated July 27, 2012</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp; &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp; &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp; &nbsp; &nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 46%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 48%">&nbsp;AETHLON MEDICAL, INC.</TD></TR>
<TR>
    <TD STYLE="border-bottom: white 3pt solid; vertical-align: top">&nbsp;</TD>
    <TD STYLE="border-bottom: white 3pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="border-bottom: white 3pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: white 3pt solid; vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By:&nbsp;<U>/s/ James A. Joyce&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&#9;</U></P></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">James A. Joyce</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Dated: July 27, 2012</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Chief Executive Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><BR CLEAR="ALL" STYLE="page-break-before: always">
EXHIBIT INDEX</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 13%">&nbsp;</TD>
    <TD STYLE="width: 87%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-weight: normal">EXHIBIT NO.</FONT></TD>
    <TD><FONT STYLE="font-weight: normal">DESCRIPTION</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-weight: normal">3</FONT></TD>
    <TD><FONT STYLE="font-weight: normal">First Amendment to By-Laws of Aethlon Medical, Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>99</TD>
    <TD>Press Release dated July 27, 2012</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3
<SEQUENCE>2
<FILENAME>aethlon_ex3.htm
<DESCRIPTION>FIRST AMENDMENT TO BYLAWS
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">Exhibit 3</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FIRST AMENDMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>BY-LAWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AETHLON MEDICAL, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Effective as of July 24, 2012, Section 1
of Article III of the By-laws of Aethlon Medical, Inc. (the &ldquo;Corporation&rdquo;) hereby is amended and restated in its entirety
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in">&ldquo;&#9;1.&#9;The number of Directors constituting the
Board of Directors shall be no less than one (1) and shall be fixed by resolution of the Board of Directors from time to time.
The Directors&rsquo; term of office shall be one (1) year, and Directors may be re-elected for successive annual terms.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">I hereby certify that (a) I am the duly
elected and acting Secretary of the Corporation, and (b) the foregoing amendment was duly adopted by resolution of the Board of
Directors of the Corporation on July 24, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IN WITNESS WHEREOF, I have hereunto subscribed my name as of
July 24, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"><U>/s/ James A. Joyce&#9;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">James A. Joyce</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">Secretary</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>3
<FILENAME>aethlon_ex9901.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">Exhibit 99</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Aethlon Medical Announces the Appointment
of Thomas V. Wornham and Philip A. Ward to its Board of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>SAN DIEGO &ndash; July 27, 2012 &ndash;
Aethlon Medical, Inc.</B> (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious
disease, cancer and other life-threatening conditions, today announced the appointment of Thomas V. Wornham and Philip A. Ward
to its board of directors. &quot;We are honored to have Tom and Phil join our board. Their wealth of business experience will be
instrumental in guiding the future growth and achievement of our organization,&rdquo; stated Aethlon Chairman &amp; CEO Jim Joyce.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Wornham recently retired as Executive
Vice President &amp; Regional Manager at Wells Fargo Bank in San Diego, representing the culmination of an exemplary career that
spanned three decades. At Wells Fargo, Tom&rsquo;s team provided financial solutions to diverse industry organizations whose annual
revenues ranged between $10 million to $1 billion dollars. Included among these organizations were public and private life science,
biotechnology and medical device companies located throughout San Diego, Imperial, and southern Riverside Counties. Mr. Wornham
is also an active civic leader. He is currently Vice Chairman of the San Diego Water Authority and the past Chairman of the San
Diego Regional Chamber of Commerce, the Century Club of San Diego, and the San Diego Regional Economic Development Corporation.
Mr. Wornham graduated from University of California Berkeley, with a B.A. Political Science in 1982.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;This is a tremendous opportunity
for me to work with Jim and his team,&rdquo; stated Mr. Wornham. &ldquo;I am excited to be part of a group committed to developing
technology that I hope will improve the quality of people's lives.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Ward is the former Chairman and CEO,
<FONT STYLE="color: black">Bignell-Ward-Bignell Corporation; former President and CEO, Hawk Financial Services Corporation, a premium
finance company; Former Executive Director and COO of Investments, Golden Eagle Insurance Corporation, a property and casualty
California insurance company; and former Executive Vice President and COO of Finance at Big Bear Supermarkets, where he was also
in charge of acquisitions, as well as leasing and sales of all operating units and real properties. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;I believe in the vision of Aethlon
Medical and I look forward to contributing my business acumen to the benefit of shareholders,&rdquo; stated Mr. Ward.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Aethlon Medical</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black">The Aethlon
Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other
life-threatening conditions. Our Aethlon ADAPT&trade; System is a revenue-stage technology platform that provides the basis for
a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system.
The Aethlon ADAPT&trade; product pipeline includes the Aethlon Hemopurifier&reg; to address infectious disease and cancer; HER2osome&trade;
to target HER2+ breast cancer, and a medical device being developed under a contract with DARPA that would reduce the incidence
of sepsis in combat-injured soldiers and civilians. For more information, please visit </FONT>www.aethlonmedical.com<FONT STYLE="color: black">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Certain statements herein may be forward-looking
and involve risks and uncertainties.&nbsp; Such forward-looking statements involve assumptions, known and unknown risks, uncertainties
and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different
from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks
and uncertainties include, without limitation, that the FDA will not approve the initiation of the Company's clinical programs
or provide market clearance of the Company's products, future human studies of the Aethlon ADAPT&trade; system or the Aethlon Hemopurifier&reg;
as an adjunct therapy to improve patient responsiveness to established cancer therapies or as a standalone cancer therapy, the
Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the
Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact
of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of
market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially
as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk
factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"># # #</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Contacts:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">James A. Joyce</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Chairman and CEO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">858.459.7800 x301</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">jj@aethlonmedical.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Jim Frakes</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">858.459.7800 x300</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">jfrakes@aethlonmedical.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Marc Robins</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">877.276.2467</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">mr@aethlonmedical.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0$`>`!X``#_VP!#``8$!08%!`8&!08'!P8("A`*"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!#`0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P``1"`!8`.L#`2(``A$!`Q$!_\0`
M'``!``(#`0$!``````````````8'!`4(`@,!_\0`3!```0,#`00&!08)"`L`
M`````0(#!``%$08'$B$Q"!-!46%Q%"*!D:$5,D)28H(7-CA4<G2SM,$8-T.4
MHK'1\",D)3,T<W62D[+#_\0`&P$!``(#`0$```````````````0%`@,&`0?_
MQ``Q$0`!`P($!`,(`@,````````!``(#!!$2(3%!!1,B46%Q@084,I&AL<'1
M(_$5%N'_V@`,`P$``A$#$0`_`.J:4I1$I2E$2E*41*4I1$I2E$2E*41*4I1$
MI2E$2E*41*4I1$I6EU5J2W:8MBIUU>W&^2$)XK<5W)'::YTUMM-O6I''&6'%
M0+<>`895A2A]M7,^7*I]%PZ:L-VY#N5$J*R.#(YGLK_OFNM.61:F[A=8Z71S
M;;)<6#W$)R1[:BK^VK2[2]U#5R='>AE('Q4*YN-*Z"/V?@:.MQ/T58_B<I/2
M`%TM#VS:5D*`=,Z,">;K`(_LDU,;)J>RWU.;3<8TE6,E"5X6/-)XCW5QQ7ME
MUQEU+C*U-N).4J2<$'P-8S>S\)'\;B#\UZSB<@/4`5V]2N=M![79]N<;B:D4
MN;".$B1S=;\3]8?'SY5?]MG1KE":EPGD/1G4[R'$'((KG:RAEI'6D&7?96M/
M4LG%VK*I2E1%(2E*41*4I1$I2E$2E*P+_>(-@M$JZ75X,08J.L>=*2K=3WX`
M)-$6?2M-I+4]HU=:$W33\L2X*EJ;#H0I/K#F,*`-;FB)2E1?3^O=.:AU#<+'
M:+B)%TMY6)+(;6GJ]Q>XKB0`<*X<#1%**4I1$I2E$2E*41*U]\ND6RVJ3<)R
M]R,P@K6>WP`\2>`\ZV%4-TA]1*7*B:?CKPVV!(D8/-1X)2?(9/M'=4NBI353
M-BVW\EHJ9N1&7JMM:ZHFZKO3DZ8HI;!*66<^JTCL`\>\]IK04JX-DNS.)?;4
MJ[:A0Z8[I(C,I44;P'-9(X\^7E7;330\/A!.31D`N=CCDJ9+#4JGZ5U#^"'1
M_P"8/?UES_&GX(=(?F#W]9<_QJO_`-@INQ^0_:E?XR;N%R]2K9U_H_2K;\^W
MZ5G)3J"VL"5)MI=*U%GF2,]H!!P#R(X<153594E9'5LQQ[*)-`^!V%Z58&R;
M7+FF+HF'-<)L\I6'`3_N5'Z8\._P\JK^E;*BG941F-XR*PCD=$X.:NX$*"TA
M22"DC((.017[5:["M1*O.DO0Y"]^5;E!DDGB6S\P_`C[M657SV>%T$CHW:A=
M3%()6!XW7RE2&XL9V0^H(9:07%J/8D#)-4^OI"Z5?>4W9+;J"\%/TH<$E)[^
M9!^%7#)8;DL.,O(2MIQ)0M"AD*!&"".ZHA>-<:)T2QZ+/N]JMH:&!%:4G>3C
ML#:.(]U:EL4:TUMYTA>KTU:)`N-HN+JPVAJXQ^J"EDX"<@G!SPXXJRKO<X=H
M@N3+E(;CQFQE2UGAY>)\*XOZ2NT"V:\?L\G3]ME(A0U.-_*CS!;Z]1W2$)/<
M,9X\>/(=MR;8;NS+UK8[3=''1:(Z$/R4M@DK*CD\!S]4`#NR:E4=-[S+@VS)
M]%'J)N2S%NIJG:S9G`MR-;[Q)C(X*D-1<H'CSK>P]=6&9INXWR++ZV';V%R)
M*4I/6-I0DJ.4\\X!QWUH(NU#242.AB.F6TRA(2E"(:@$@=@&*@VE[C#?VU(?
MT^VZFU7%"D/-K:*$G+9*O5/9O`&I9HVO:ZS"VPN+G6WHHXJ2US>H.N;9;*OX
MFW.+^'23>Y=VNZM&ALI8B85A)+*4YZK./G[Q]M6CKC:%8]H6P_6\K3JY"FHL
M;JG.N:W#DX(Q4+LD9@]-&\,EEHLAC@C<&[_PC?95O[=X[+&QO5@8:;:!A*)"
M$A.>([JJE8*K-@NT/3F@=B$-_4<[JEO3)!9CMIWW7<*'S4CL\3@>-2.+TG=$
M.RTM2(UYBMJ/!UR.D@#O("B<>0-1/HB:"ML[3TC5-XBMRY0D*C0DOIWTL(3@
MJ4D'@"5*/'LQPYFKHVMZ2L^H=`WIB?!CJ4S#==8=#8WVEI02E23S'$#S'"B*
M56.[P;[:X]QM,EN5!D)WVGFSE*A_GACLKFGH[?E%;2/TYG[V*D70LEO/;.+K
M&<65-Q[FKJP3\T*;02!X9R?,FH[T=ORBMI'Z<S][%$71&L-5V71]I-QU#.:A
MQ<[J2OBI:OJI2.*CX"JG<Z36C@LJ1;K\Y%!P9"8R=WXKJ%7U@;4>E$;%=RMZ
MPV)"O]6)]500D%6?TG%`$\RD`5T\S;83,),-F)';B)3NAE+20@#NW<8Q1%H]
M#Z[T]K>WJEZ;N#<I*#AUL@I<:)Y;R3Q&>_D:P]<[2+!HFZ6FWWQ<E,FYJ*8X
M9:WQD*2GB>SBH50FLH3&R7I'Z=G6`)B6B^;B),9'JMI"W.K<`'U1ZJP._P`!
M3IIAXZBT6F(5"04/=7N'!WM]O&/'-$5JZSV^:+TO=';:MZ7<IS*BEUN"T%I;
M4.8*B0,^6<=N*_=$;>]%ZMNC%LCORH$]\A+3<UL(#BCR2E0)&?`D9[*D^SO0
M%ET5IZ-;X$..J0E"?2)2FP7'W,>LI2N?$YP.P50?3)TW;;2C3]_MD9N)<7GU
MLNN1TA'682%)4<?2!!P>?'P%$75M<?[0+@JZ:VO4I1R%25H2?LI.ZGX)%=8V
M"2Y-L5NE/8ZU^,VZO'>I()_OKC>ZY^4YF]\[KEY\]XYKHO9YH,CW>`53Q8G"
MT+9Z*T^[J;4D.V-9"%JWGECZ#8XJ/^>TBNO(,5F%$9C1D);890&T(')*0,`5
M6^PK2OR/IXW24WB;<`%)WAQ0S]$>WG[NZK0J'QBL]XGPM^%OWW6[A]/RH\1U
M*5'-H>J8FC-(7&^SB"W$:*D-DX+CAX(0/-1`J1UQGTN]?&\ZE:TI`=S!M:NL
MDD'@N01R^ZDX\U*[JJ58*HK5KB[P=?MZN+O6W7TLRG"KDYO'UD'[)22G'<:N
M;5L.(B3%NEGRJRW9H3(9^JE7SFSXH5E)'@*YPJ[-BMV&H;!/T1*5O2T%4^S$
M\^L`RZR/TDC>`[TGOJRX55^ZSB_PG(J%74_.CRU"^M*$$$@C!%*[L%<XK/Z/
ML]4;6CL0G_1RXRD[OVDD*!]P5[ZZ2KE;8GG\)EGQG^FSY=2NNJ:XSCS0VJN-
MP/RK_A9)AMV*ISI5ZDNNFMEX=LDAR,],FHANO-$A:&U(6HX(Y9W`,^-8>P_9
M)H^-H^SWN5"CWFZ3HS<IR3*`=2E2T[Q2E)X#!.,D9R#GNJU]6Z;MFK+%)L]\
MCB1!D#"TYP00<A23V$$9S536_H_)M"%Q[%KO55N@*)(C,R`D#//E@9\<52JQ
M45Z;#3;&FM*MLH0VVF2\$I0,`>JGD*E6T<*TYM'TWJ9U"C`6A#;J@,[I&0K^
MRK(\C6_U#L6LFHM(V2P7>Y79]JUK<<1)ZX%YY;A)4I:E).<DFK`N]F@WBV*M
M]RCHD15``I5X<B#V'Q%2:2<028G"X-P?(K141&5EAKJ%DPGX\V,W(BK;=8<`
M4A:""%`]H->]]H/!O*`[C>">&<=^/:*K5.R*)&4M-KU!>H,=1SU3;W#X8J0Z
M.T)!TO-?FLRYDR8\WU:W9*PH[N<\.'>!7LD<`!+)"?"WW7C'RD@.9;U5&6R0
MU&Z;%TZ]Q*.M;ZM&\<;RC#00//@:N#;XH'8[JP`C(A'(SXBM-M-V%V'7=_3>
MW)LVVW0I2EQV-ND.;H`2H@CYP``R#R`K+TUL;M5FT9?=..W6Z36+S@2'WEIZ
MP`<@DXX=O/-15(6FZ(G\SD?]=?\`[Q5GZU_$R_?J$C]FJL+9UHNW:"TVBR6=
MV2[$2ZMT*D*"EY4>/$`#X5O;K";N5LEP7BI+4EE;*RGF`I)!QX\:(N?^A-^(
M=]_ZE_\`)%:7H[?E%;2/TYG[V*O'9?L[M.SBTR[?9'YCS,E_KUF2M*E!6Z$\
M,`<,`5B:.V76;2>LKUJ6W2)KDZ[%TOH>6DMIWW.L.Z`D$<1VDT7BI2X24[-.
ME:_<[PKJ+-?4*Q)5P2E+B4Y)/<'4`'N&#74C<AMQD.MK2II2=X+2H$$=^:C^
MO=$6+75I%OU%##[2"5-.).ZXTH\,I5V>7(]HJJ/Y-EO0RJ)'UCJ1JV$\8@=3
MN8[L8Q\*+U0_:-*8VG=)'3-HL2DRH-F*#+?;XH]1SK'?6Y8P$HS]8UF]+7^<
M#9S_`,Y7[5JKMV=[-].[/X;C.GHA2ZZ`'I+RM]YW'>KN\``*QMH>S"S:[N]F
MN-VD36G[4HJ8$=:4I42I*O6RD]J1RQ1%.ZYKZ;WXJZ:_77/V==*5"-J6S:T;
M2($&)?'YC+<1Q3J#%6E))(P<Y2:(I%I+\5;-^I,_LTU0$'1"[KM@N5L>01!C
MRER7SC^B)WDI]N\![SV5T9;HB($"-$:*BVPTEI)5S(2,#/NKPQ`C,3),MIE"
M9,@)#K@'%82,)SY9J925CJ4/PZN%E'J*<3%N+8K)0A*$A*0`D#``&`!7JE*A
MJ0HSM!U(WI;3$JX$I+^.KCH/TW#R]@YGP%<%;2(#CDXW=14M<A9+ZCS*SQWC
MYU?^VW5/R[J8P8SF]`MQ+:<'@MSZ2O81@>7C597"(W.A/1GAE#B2/+N/OKJ:
M7A(=1$.'4[,>';_OFJ26NM4`CX1DJ6K-LMSE6:[1+E;W2U+BNI>:6.Q23D5\
MI\5R%+=C/##C:BDUCUR[FEI(.H5T""+A=):H5%O$.W:KM381`O*"XMM)R(\D
M<'6C][B.\&H]6LV$7IN8N?HFY.A$:[D.P'%G@S-2/4\@L>H?NUMWV7([[C+Z
M"AUM10M*A@I(."#7:<&K/>(<#CU-^VRYZO@Y,EQH59?1\MZI.M79>#U<2,I6
M?M*(2![M[W5TE5:["M.JLVDO39*-R5<E!X@CB&P/4'Q)^]5E5SG%IQ/5.(T&
M7R5M01F.$7U.:4I2JU3$I2E$2E*41*CVO[G)L^C[I<(*PB2PUO(44@@'([#4
MAK4:JLZ;_I^;:U/%E,E&X7`G>W>(/+V5G$6A[2[2^:PD!+2&ZJMKOKR\,Z)B
MF,MM.HTR'V9.4`A(8"E.''+EN?\`=7UO.K;HW?[1#^64VV/(L[4UQWT+T@ET
MJ((P.(SCRX5()NSN))O-^N`EK0JZ1EL!O<REE2TI"UCCQ)W17N5HF6+Q`N5L
MO1AR(MN1;L^C)<"DI).<$\,_PJR$U)D`!OMN=M#IIHH7+GW/;Z?O5:ZZ7.^?
M*6D+7;[VC?NB)*W9JH0]<(2%I(;)X<.'.L>X:FOUC7J"U7"5'E3(EM-QB3&V
M=S*=[=(4C)&<UO;KI*XW"58YORZ6[I:P\!(]$20YU@`/JYP,#A7S3H-+L.\F
MX71^9<[HQZ.Y+<;`ZM'8E"!P`[<9K6V2"PQ6/?+?%KII;^ED62W-K_/P_:US
M>H;W>KG9K-:Y3,-]RU-7&9,6R%GUL#=0G..9^/A6SU3>9NC]%R'Y]P;G7%:^
MJC.J:2T"M7S<C..'$GP%?LK1)"[5*M=S=@72!$3#$E+06EUL#&%H//CQY_PK
MT='2IUUM<W4%W%R$$K6EDQ4MH4M0P"0">7#'CVUB7P%S2+81J+9GUMNL@V4`
MC<[[*-V[6\]W1&IG#.B2;O:%'=DL!*FW$$^HL`<.\>RK'L,AR79+?)?(+KT=
MMQ9`QDE()J+:@V?Q[E/FR84KT!$R$8;[+3(*5C>R%<QQ&!7I-DU/:;0IB!?6
MICB&4L1VW8J6TM\4C>)!).$YX=M8S<B1O\9`)._D/"VJ1\UAZ@2+*7SW%-09
M#J#A:&U*'F!512-::G7IC2$JWEJ1/G^DN/M]6!UP:)5NCN)2DCA5N.1U.P%1
MW'=Y2F]Q3F.9Q@G%12SZ&1;6],)$Y3GR&7RG+>.NZT$<>/#&?&L::2%@/,%S
M?\'\V6<[)'D83;^Q^+K`1KE,FZ19<1>_:%69^X+;P-X+;4,@GL(XC'?7VTB=
M3WV%`O4N\1XT>04O""U%"D]5GYI63G)';V9K[V[9]!@ZJGW9E]1BS&7&EP2C
MU$]9N[Y!SP!QRQVUZLFDKG8U,1K=J-X6=EP*3$>BH<6$9R4!S.<=G+A6Q[X,
M)$=@<M1YY:'/Q^JUM;+BN_3P*FE0C:SJD:8TJ\MA>[/E98C@'B"1Q7]T?''?
M4GM<67%7,,R>N6EUXN-)4V$=2@\D#'/'>>-4AMVL.HYE[^4C&5(M#+80R6,J
MZH<U%8Y@D]O+`'&O.'0QRU+6R$8?OX+*KE>R(EHS5.DDDDG)/;2E*[\+FE#M
M>V=4A+<Z,VI3@PAP)&21V'^'NJ$^@R_S5_\`\9JYZ]M-K><2VTA2W%'"4I&2
M3W`525G!HZB0RXL-]<E8P<1=$P,PW5,QX\^,^V\PQ);=;4%H6A"@4J!R"#YU
MUYH#3S6T]=HU9+0&&EIW;K&*2DJE-X!W1]58W5>&3VUYT%LBG7-QN7J,+A0A
M@ACDZYY_5'GQ\N==`6Z#&ML)J)"90S&:2$H;0,!(J@F+*%Y%-)<Z'+)63`ZJ
M:#,RP62A(0D)2`$@8`'97[2E5BFI2E*(E*4HB4I2B)2E*(E*4HB4I2B)2E*(
ME*4HB4I2B)2E*(E*4HBC%\T+IR]K4Y/M4<O*XEUH%M9/>2G&?;46?V)Z8=5E
M#]S9'U4/)(^*32E2(ZVHB%F/(]5I=31/-W-"^D/8QI:.H%TSY('8Z^!_Z@5,
MK%IBS6)/^R;=&C*Q@K2C*R/%1XGWTI6+ZN>86D>3ZHRGCC/2T!;JE*5I6Y*4
%I1%__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
